A Comprehensive Longitudinal Cohort Study in Type 2 Diabetes With High Risk of Cardiovascular Diseases in China (CCMR-3B Ext)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01307410|
Recruitment Status : Unknown
Verified February 2011 by China Cardiometabolic Registries.
Recruitment status was: Active, not recruiting
First Posted : March 2, 2011
Last Update Posted : February 15, 2013
|Condition or disease|
|Type 2 Diabetes|
Limited by its cross sectional design, 3B study was not be able to provide any information on how various patterns of treatment and prescribing behaviors would impact the outcomes of prevention of cardiovascular and cardio-renal diseases in type 2 diabetes longitudinally. This information, however, would be crucial in better guiding the real world medical practice and maximizing the effectiveness of medical treatment for better controlling cardiovascular risk factors.
The 3B Extension study is thus designed to extend the 3B study by continuing to follow up on enrolled patients for 3 years. The 3B Extension study is expected to demonstrate the clinical outcomes of nationally representative type 2 diabetes patients who are treated by endocrinologists, cardiologists and nephrologists separately in all tiers of hospitals, as measured by diabetes progression, incidence of cardiovascular complications, and incidence of microvascular complications. It will be the first study of this scale in China based on its exclusivity, extensiveness, and the level of government and national thought leaders' support. It will be conducted in collaboration with the advisory board of China Cardiometabolic Registries (CCMR).
|Study Type :||Observational|
|Estimated Enrollment :||5000 participants|
|Official Title:||A Comprehensive Longitudinal Cohort Study in Type 2 Diabetes With High Risk of Cardiovascular Diseases in China - 3B Extension A Study of China Cardiometabolic Registries (CCMR)|
|Study Start Date :||March 2011|
|Estimated Primary Completion Date :||May 2014|
|Estimated Study Completion Date :||December 2014|
Patients with hypertension and dyslipidemia with prior CAD
Patients with hypertension and dyslipidemia without prior CAD
- Incidence of CVD events [ Time Frame: 3 years ]
The CVD event is defined as composite of :
- Acute myocardial infarction
- Cardiovascular death
- Annual incidence of microvascular complications [ Time Frame: 3 years ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01307410
|Principal Investigator:||Linong Ji, MD||People's Hospital, Beijing University|
|Principal Investigator:||Dayi Hu, MD||People's Hospital, Beijing University|